Drugs / Transcrocetin
Transcrocetin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04378920 | Apr 2020 → Aug 2021 | acute respiratory distress syndrome, infectious disease with sepsis | Institut de cancérologie Strasbourg Europe | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06477939 Comparator | Jan 2025 → Dec 2032 expected | glioblastoma | Institut de cancérologie Strasbourg Europe | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Transcrocetin | “Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients” NCT06477939 ↗1“Patient is treated with LEAF-4L6715, a liposomal transcrocetin.” NCT04378920 ↗ |
| Known as | L-TC | “Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients” NCT06477939 ↗ |
| Known as | LEAF-4L6715 | “Patient is treated with LEAF-4L6715, a liposomal transcrocetin.” NCT04378920 ↗ |
| Known as | Liposomal Transcrocetin | “Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients” NCT06477939 ↗ |
| Known as | Liposomal Trasncrocetin | “This is phase III randomized, multicenter study adding or not intra-venous Liposomal Trasncrocetin (L-TC) to hypofractionated radiotherapy and concomitant Temozolomide followed...” NCT06477939 ↗ |
| Route | Intravenous | “as an IV perfusion” NCT06477939 ↗ |